NanoLogix, Inc. Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization

HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape – 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.

Help employers find you! Check out all the jobs and post your resume.